RESULTS (Continued)

1. Anti-MTB activities of DC-159a

The results for the DC-159a activities are listed in Table 1. The lowest minimum inhibitory concentration (MIC) values were obtained from DC-159a against 14 strains, and were active to rifampicin (RFP) against 11 strains, doxorubicin (DOX) against 8 strains, and levofloxacin (LVFX) against 5 strains. DC-159a demonstrated the best anti-MTB activity of all the tested drugs against DS-TB isolates, as the MIC90 values for DS-TB isolates (0.50 µg/ml) were equal to that of LVFX against DS-TB isolates (0.50 µg/ml) (Table 1). Moreover characteristically, DC-159a proved to be the most active drug among the tested drugs against QR-MDR-TB isolates, as the MIC90 values for QR-MDR-TB isolates (0.50 µg/ml) was equal to that of LVFX against QR-MDR-TB isolates (0.50 µg/ml) (8). MIC90 of DC-159a against DS-TB isolates (0.50 µg/ml) was also superior to that of LVFX against DS-TB isolates (0.50 µg/ml).

The results for the DC-159a activities are listed in Table 1. The lowest minimum inhibitory concentration (MIC) values were obtained from DC-159a against 14 strains, and were active to rifampicin (RFP) against 11 strains, doxorubicin (DOX) against 8 strains, and levofloxacin (LVFX) against 5 strains. DC-159a demonstrated the best anti-MTB activity of all the tested drugs against DS-TB isolates, as the MIC90 values for DS-TB isolates (0.50 µg/ml) were equal to that of LVFX against DS-TB isolates (0.50 µg/ml) (Table 1). Moreover characteristically, DC-159a proved to be the most active drug among the tested drugs against QR-MDR-TB isolates, as the MIC90 values for QR-MDR-TB isolates (0.50 µg/ml) was equal to that of LVFX against QR-MDR-TB isolates (0.50 µg/ml) (8). MIC90 of DC-159a against DS-TB isolates (0.50 µg/ml) was also superior to that of LVFX against DS-TB isolates (0.50 µg/ml).

The results for the DC-159a activities are listed in Table 1. The lowest minimum inhibitory concentration (MIC) values were obtained from DC-159a against 14 strains, and were active to rifampicin (RFP) against 11 strains, doxorubicin (DOX) against 8 strains, and levofloxacin (LVFX) against 5 strains. DC-159a demonstrated the best anti-MTB activity of all the tested drugs against DS-TB isolates, as the MIC90 values for DS-TB isolates (0.50 µg/ml) were equal to that of LVFX against DS-TB isolates (0.50 µg/ml) (Table 1). Moreover characteristically, DC-159a proved to be the most active drug among the tested drugs against QR-MDR-TB isolates, as the MIC90 values for QR-MDR-TB isolates (0.50 µg/ml) was equal to that of LVFX against QR-MDR-TB isolates (0.50 µg/ml) (8). MIC90 of DC-159a against DS-TB isolates (0.50 µg/ml) was also superior to that of LVFX against DS-TB isolates (0.50 µg/ml).